{"id":128779,"date":"2024-07-17T13:20:30","date_gmt":"2024-07-17T07:50:30","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=128779"},"modified":"2024-07-17T13:20:34","modified_gmt":"2024-07-17T07:50:34","slug":"pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/","title":{"rendered":"Pharma stocks in which FIIs increased their stake by up to 3.45% in Q1"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3501706210\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>India is the largest global supplier of generic drugs and the Indian pharmaceutical industry is growing rapidly, projected to reach $65 billion by 2024 and $130 billion by 2030. Growth is driven by increasing R&amp;D investments, government initiatives, and rising domestic healthcare demand&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2229794408\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>Foreign Institutional Investors (FIIs) increasing their holding stake in certain companies indicate a positive outlook on the company&#8217;s performance, management, and prospects, thereby leading to speculation of expected future growth and upcoming changes in the company.&nbsp;<\/p><p><strong>Listed below are some of the Pharmaceutical stocks in which FII\/FPI have increased their stake in Q1FY25&nbsp;<\/strong><\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/SHILPAMED\/consolidated\" target=\"_blank\" rel=\"noreferrer noopener\">Shilpa Medicare&nbsp;<\/a><\/strong><\/h2><p>Shilpa Medicare Limited is engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and formulations for both domestic and international markets.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-1977743840\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>With a market capitalization of Rs. 6,317 Crores, the shares of Shilpa Medicare Limited closed on Tuesday\u2019s trade at Rs. 646.05 per share, down 1.22 percent from its previous day\u2019s close price of Rs. 654.&nbsp;<\/p><p><strong>In Q1FY25 the FII\/FPI increased their holding in Shilpa Medicare Limited from 5.63 percent in Q4FY24 to 3.63 percent in Q1FY25 by purchasing an additional 3.45 percent stake&nbsp;<\/strong><\/p><p>Its Revenue from Operations grew by 10.08 percent from Rs. 1,046 Crores in FY23 to Rs. 1,152 Crores in FY24, accompanied by a loss of Rs. 31 Crores to a profit of Rs. 32 Crores.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/GLAND\/standalone\" target=\"_blank\" rel=\"noreferrer noopener\">Gland Pharma&nbsp;<\/a><\/strong><\/h2><p>Gland Pharma Limited is engaged in the business of pharmaceutical research, development, manufacturing, and marketing of complex injectables with a strong presence in injectables, oncology, and ophthalmology segments.&nbsp;<\/p><p>With a market capitalization of Rs. 33,829 Crores, the shares of Gland Pharma Limited closed on Tuesday\u2019s trade at Rs. 2,053.35 per share, up 2.63 percent from its previous day\u2019s close price of Rs. 2,000.65.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Also read<\/strong><\/p><\/blockquote><figure class=\"wp-block-embed is-type-wp-embed is-provider-trade-brains wp-block-embed-trade-brains\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"yQ15oCtmDo\"><a href=\"https:\/\/tradebrains.in\/features\/financially-strong-stocks-under-50-to-keep-in-your-radar\/\">Financially strong stocks under \u20b9 50\u00a0to keep in your radar<\/a><\/blockquote><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;Financially strong stocks under \u20b9 50\u00a0to keep in your radar&#8221; &#8212; Trade Brains\" src=\"https:\/\/tradebrains.in\/features\/financially-strong-stocks-under-50-to-keep-in-your-radar\/embed\/#?secret=ewlOFuU88n#?secret=yQ15oCtmDo\" data-secret=\"yQ15oCtmDo\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure><p><strong>In Q1FY25 the FII\/FPI increased their holding in Gland Pharma Limited from 3.59 percent in Q4FY24 to 6.88 percent in Q1FY25 by purchasing an additional 3.29 percent stake&nbsp;<\/strong><\/p><div class=\"trade-content-10\" id=\"trade-3196108271\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>Its Revenue from Operations grew by 56 percent from Rs. 3,625 Crores in FY23 to Rs. 5,665 Crores in FY24, accompanied by profits of Rs. 781 Crores to Rs. 772 Crores.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/MARKSANS\/consolidated\" target=\"_blank\" rel=\"noreferrer noopener\">Marksans Pharma&nbsp;<\/a><\/strong><\/h2><p>Marksans Pharma Limited is engaged in the business of research, manufacture, marketing, and sale of pharmaceutical formulations across various therapeutic areas, such as pain management, cough and cold, cardiovascular, central nervous system, and many more.&nbsp;<\/p><p>With a market capitalization of Rs. 8,510 Crores, the shares of Marksans Pharma Limited closed on Tuesday\u2019s trade at Rs. 187.80 per share, up 0.13 percent from its previous day\u2019s close price of Rs. 187.55.&nbsp;<\/p><p><strong>In Q1FY25 the FII\/FPI increased their holding in Marksans Pharma Limited from 15.57 percent in Q4FY24 to 18.59 percent in Q1FY25 by purchasing an additional 3.02 percent stake&nbsp;<\/strong><\/p><p>Its Revenue from Operations grew by 17.56 percent from Rs. 1,852 Crores in FY23 to Rs. 2,177 Crores in FY24, accompanied by profits of Rs. 265 Crores to Rs. 315 Crores.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/MANKIND\/consolidated\" target=\"_blank\" rel=\"noreferrer noopener\">Mankind Pharma&nbsp;<\/a><\/strong><\/h2><p>Mankind Pharma Limited is one of the leading players in the pharmaceutical industry, it is engaged in developing, manufacturing, and selling a diverse range of markets pharmaceutical formulations across various acute, and chronic therapeutic areas and several consumer healthcare products.<\/p><p>With a market capitalization of Rs. 84,714 Crores, the shares of Mankind Pharma Limited closed on Tuesday\u2019s trade at Rs. 2,114.50 per share, down 1.55 percent from its previous day\u2019s close price of Rs. 2,147.70.&nbsp;<\/p><p><strong>In Q1FY25 the FII\/FPI increased their holding in Mankind Pharma Limited from 9.87 percent in Q4FY24 to 11.58 percent in Q1FY25 by purchasing an additional 1.71 percent stake\u00a0<\/strong><\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Also read<\/strong><\/p><\/blockquote><figure class=\"wp-block-embed is-type-wp-embed is-provider-trade-brains wp-block-embed-trade-brains\"><div class=\"wp-block-embed__wrapper\">\n<blockquote class=\"wp-embedded-content\" data-secret=\"GyATm7obvM\"><a href=\"https:\/\/tradebrains.in\/features\/3-stocks-in-which-hdfc-group-bought-fresh-stake-of-up-to-3-5-in-q1\/\">3 Stocks in which HDFC Group bought fresh stake of up to 3.5% in Q1\u00a0<\/a><\/blockquote><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;3 Stocks in which HDFC Group bought fresh stake of up to 3.5% in Q1\u00a0&#8221; &#8212; Trade Brains\" src=\"https:\/\/tradebrains.in\/features\/3-stocks-in-which-hdfc-group-bought-fresh-stake-of-up-to-3-5-in-q1\/embed\/#?secret=YczeNTknd7#?secret=GyATm7obvM\" data-secret=\"GyATm7obvM\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe>\n<\/div><\/figure><p>Its Revenue from Operations grew by 14 percent from Rs. 8,127 Crores in FY23 to Rs. 9,265 Crores in FY24, accompanied by profits of Rs. 1,248 Crores to Rs. 1,823 Crores.&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by: Bharath K.S<\/strong><\/p><\/blockquote><h4 class=\"wp-block-heading\" id=\"h-disclaimer\"><strong>Disclaimer<\/strong><\/h4><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-2782701264\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>India is the largest global supplier of generic drugs and the Indian pharmaceutical industry is growing rapidly, projected to reach $65 billion by 2024 and $130 billion by 2030. Growth is driven by increasing R&amp;D investments, government initiatives, and rising domestic healthcare demand&nbsp; Foreign Institutional Investors (FIIs) increasing their holding stake in certain companies indicate [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":111747,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[4023,9339,19821,9055,20576,8864,19035,13155,948,936,2597],"class_list":["post-128779","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-gland-pharma","tag-gland-pharma-share-price","tag-mankind-pharma","tag-mankind-pharma-share-price","tag-marksans-pharma","tag-marksans-pharma-share-price","tag-shilpa-medicare","tag-shilpa-medicare-share-price","tag-stock-market","tag-stock-market-news","tag-stocks-to-watch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stocks in which FIIs increased their stake by up to 3.45% in Q1 - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"India is the largest global supplier of generic drugs and the Indian pharmaceutical industry is growing rapidly, projected to reach $65 billion by 2024 and $130 billion by 2030.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stocks in which FIIs increased their stake by up to 3.45% in Q1\" \/>\n<meta property=\"og:description\" content=\"India is the largest global supplier of generic drugs and the Indian pharmaceutical industry is growing rapidly, projected to reach $65 billion by 2024 and $130 billion by 2030.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-17T07:50:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-17T07:50:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/\",\"name\":\"Pharma stocks in which FIIs increased their stake by up to 3.45% in Q1 - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"datePublished\":\"2024-07-17T07:50:30+00:00\",\"dateModified\":\"2024-07-17T07:50:34+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"India is the largest global supplier of generic drugs and the Indian pharmaceutical industry is growing rapidly, projected to reach $65 billion by 2024 and $130 billion by 2030.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stocks in which FIIs increased their stake by up to 3.45% in Q1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stocks in which FIIs increased their stake by up to 3.45% in Q1 - Trade Brains Features","description":"India is the largest global supplier of generic drugs and the Indian pharmaceutical industry is growing rapidly, projected to reach $65 billion by 2024 and $130 billion by 2030.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stocks in which FIIs increased their stake by up to 3.45% in Q1","og_description":"India is the largest global supplier of generic drugs and the Indian pharmaceutical industry is growing rapidly, projected to reach $65 billion by 2024 and $130 billion by 2030.","og_url":"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2024-07-17T07:50:30+00:00","article_modified_time":"2024-07-17T07:50:34+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/","url":"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/","name":"Pharma stocks in which FIIs increased their stake by up to 3.45% in Q1 - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","datePublished":"2024-07-17T07:50:30+00:00","dateModified":"2024-07-17T07:50:34+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"India is the largest global supplier of generic drugs and the Indian pharmaceutical industry is growing rapidly, projected to reach $65 billion by 2024 and $130 billion by 2030.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stocks-in-which-fiis-increased-their-stake-by-up-to-3-45-in-q1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stocks in which FIIs increased their stake by up to 3.45% in Q1"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/128779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=128779"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/128779\/revisions"}],"predecessor-version":[{"id":128786,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/128779\/revisions\/128786"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/111747"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=128779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=128779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=128779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}